BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 16, 2005
View Archived Issues
FDA Sends Second Approvable Letter For Celgene's Thalomid
Celgene Corp.'s Thalomid (thalidomide) again is approvable for multiple myeloma, but only after certain conditions are met, the FDA said. (BioWorld Today)
Read More
AVI Brings In $23M For Third-Generation Antisense Drugs
Read More
Korea Touts Itself As Growth Region For Biotech Investing
Read More
Gilead: Five-Year Hepsera Data Show Continued Efficacy In HBV
Read More
Other News To Note
Read More